Afamelanotide is indicated for:
Irrespective of gender only Adults (18 - 65 years old)
Afamelanotide is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Afamelanotide is contraindicated in the following cases: